Improving frailty and long-term outcomes after kidney transplantation

改善肾移植后的虚弱和长期结果

基本信息

  • 批准号:
    10677843
  • 负责人:
  • 金额:
    $ 15.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-11 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Improving the long-term survival of kidney transplants (KT) is a national priority in the US. The prevalence of end-stage renal disease is increasing, and the organ shortage is growing. Unfortunately, long-term graft and patient survival has not improved since the 1990s. The half-life of a deceased donor kidney is currently only fifteen years. The most common cause of kidney transplant failure is patient death. In order to address this health crisis, the transplant community needs to focus on modifiable risk factors for patient death and other adverse long-term outcomes after kidney transplantation, such as frailty. Frailty is a clinical syndrome characterized by decreased physiologic reserve and is common in patients with chronic kidney disease (CKD). Frailty prior to KT has been associated with increased post-transplant mortality and has been shown to be modifiable in non-transplant patients. However, there is a significant knowledge gap regarding frailty after KT, including risk factors for its development, biomarkers with which to identify it, and interventions with which to improve it. Cellular senescence is an exciting new area of frailty research that directly applies to these deficits. During the process of senescence, metabolic stressors cause cells to enter a state of permanent growth arrest. Senescent cells accumulate throughout the body and secrete factors collectively called the senescence- associated secretory phenotype (SASP) which induce formation of other senescent cells and cause surrounding tissue damage. Cellular senescence is a mechanism of aging and age-related diseases such as frailty. Components of the SASP serve as biomarkers of frailty in non-transplant populations and may help us identify KT recipients at high risk of functional decline and premature death. In addition, frailty biomarkers could ultimately serve as surrogate endpoints in clinical trials designed to improve frailty. The overall objective of this application is to 1) identify frailty trajectories after kidney transplantation, 2) identify biomarkers of frailty after kidney transplantation, and 3) conduct a phase II clinical trial examining the preliminary efficacy, feasibility and acceptability of an exercise intervention on post-transplant frailty. The proposed K23 application involves the use of innovative biomarkers and behavioral interventions to improve frailty and long-term outcomes after KT, a priority for the NIDDK which focuses on bridging translational research gaps to improve the health and quality of life of patients with CKD. The candidate has exceptional resources available to her: a multidisciplinary team of expert mentors; access to a large volume of transplant patients; and excellent career development activities, i.e., formal courses and workshops in statistical methods, biomarker development, and behavioral clinical trials. Together, these resources will allow the candidate to achieve her long-term goal of becoming an independent investigator and nationally recognized expert on the use of biomarker technology and behavioral interventions to improve frailty and long-term outcomes after KT.
项目总结/摘要 提高肾移植(KT)的长期存活率是美国的国家优先事项。之时尚 终末期肾病正在增加,器官短缺也在加剧。不幸的是,长期的移植和 自20世纪90年代以来,患者存活率没有改善。一个死去的捐赠者肾脏的半衰期目前只有 十五年肾移植失败的最常见原因是患者死亡。为了解决这一 健康危机,移植界需要关注患者死亡和其他可改变的风险因素 肾移植后的长期不良后果,如虚弱。虚弱是一种临床综合症 其特征在于生理储备减少,并且在慢性肾病(CKD)患者中常见。 KT前的虚弱与移植后死亡率增加有关, 在非移植患者中可以改变。然而,在KT后虚弱方面存在重大知识差距, 包括其发展的风险因素,识别它的生物标志物,以及 细胞衰老是一个令人兴奋的新领域的脆弱性研究,直接适用于这些赤字。 在衰老过程中,代谢应激源导致细胞进入永久性生长停滞状态。 衰老细胞在整个身体中积累并分泌统称为衰老的因子- 相关分泌表型(SASP),其诱导其他衰老细胞的形成并引起 周围组织损伤细胞衰老是衰老和年龄相关疾病的一种机制, 脆弱SASP的组成部分作为非移植人群虚弱的生物标志物, 识别处于高功能衰退和过早死亡风险的KT接受者。此外,脆弱的生物标志物可以 最终作为临床试验的替代终点,旨在改善虚弱。本报告的总体目标 本发明的应用是1)鉴定肾移植后的虚弱轨迹,2)鉴定肾移植后虚弱的生物标志物, 肾移植,以及3)进行II期临床试验,检查初步疗效,可行性和 运动干预对移植后虚弱的可接受性。建议的K23应用程序涉及 使用创新的生物标志物和行为干预来改善KT后的虚弱和长期结果, NIDDK的优先事项,重点是弥合转化研究的差距,以改善健康和 CKD患者的生活质量。候选人拥有特殊的资源:a 多学科专家导师团队;接触大量移植患者;以及出色的职业生涯 发展活动,即,统计方法、生物标志物开发和 行为临床试验总之,这些资源将使候选人实现她的长期目标, 成为一名独立的研究者和国家认可的生物标志物技术使用专家 和行为干预,以改善KT后的虚弱和长期结果。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Relationship Between Health Literacy and Outcomes Before and After Kidney Transplantation.
  • DOI:
    10.1097/txd.0000000000001377
  • 发表时间:
    2022-10
  • 期刊:
  • 影响因子:
    2.3
  • 作者:
  • 通讯作者:
Kidney Transplant Outcomes of Patients With Multiple Myeloma.
  • DOI:
    10.1016/j.ekir.2022.01.003
  • 发表时间:
    2022-04
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Heybeli, Cihan;Bentall, Andrew J.;Alexander, Mariam Priya;Amer, Hatem;Buadi, Francis K.;Dispenzieri, Angela;Dingli, David;Gertz, Morie A.;Issa, Naim;Kapoor, Prashant;Kukla, Aleksandra;Kumar, Shaji;Lorenz, Elizabeth C.;Rajkumar, S. Vincent;Schinstock, Carrie A.;Leung, Nelson
  • 通讯作者:
    Leung, Nelson
Development and Validation of a Kidney-Transplant Specific Measure of Treatment Burden.
  • DOI:
    10.1186/s12882-022-02923-3
  • 发表时间:
    2022-09-03
  • 期刊:
  • 影响因子:
    2.3
  • 作者:
    Lorenz, Elizabeth C.;Petterson, Tanya M.;Zaniletti, Isabella;Lackore, Kandace A.;Johnson, Bradley K.;Mai, Martin L.;Nair, Sumi S.;Bentall, Andrew J.;Yost, Kathleen J.;Eton, David T.
  • 通讯作者:
    Eton, David T.
Physiological Age by Artificial Intelligence-Enhanced Electrocardiograms as a Novel Risk Factor of Mortality in Kidney Transplant Candidates.
人工智能增强心电图的生理年龄作为肾移植候选者死亡的新危险因素。
  • DOI:
    10.1097/tp.0000000000004504
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Lorenz,ElizabethC;Zaniletti,Isabella;Johnson,BradleyK;Petterson,TanyaM;Kremers,WalterK;Schinstock,CarrieA;Amer,Hatem;Cheville,AndreaL;LeBrasseur,NathanK;Winkelmayer,WolfgangC;Navaneethan,SankarD;Baez-Suarez,Abraham;Attia,
  • 通讯作者:
    Attia,
Guiding Kidney Transplantation Candidates for Effective Weight Loss: A Clinical Cohort Study.
指导肾移植候选者有效减肥:临床队列研究。
  • DOI:
    10.34067/kid.0001682022
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kukla,Aleksandra;Diwan,Tayyab;Smith,ByronH;Collazo-Clavell,MariaL;Lorenz,ElizabethC;Clark,Matthew;Grothe,Karen;Denic,Aleksandar;Park,WalterD;Sahi,Sukhdeep;Schinstock,CarrieA;Amer,Hatem;Issa,Naim;Bentall,AndrewJ;Dean,Patr
  • 通讯作者:
    Dean,Patr
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth C. Lorenz其他文献

A Randomized Trial of Administration of Metformin in PKD (Tame PKD)
  • DOI:
    10.1053/j.ajkd.2021.03.006
  • 发表时间:
    2021-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Elizabeth C. Lorenz;John C. Lieske;Barbara M. Seide;Julie B. Olson;Ramila Mehta;Dawn S. Milliner
  • 通讯作者:
    Dawn S. Milliner
Trends in Kidney Allograft Failure Among First-Time Transplant Recipients in the United States
美国首次肾移植受者中同种异体肾移植失败的趋势
  • DOI:
    10.1053/j.ajkd.2024.09.005
  • 发表时间:
    2025-03-01
  • 期刊:
  • 影响因子:
    8.200
  • 作者:
    Pascale Khairallah;Elizabeth C. Lorenz;Amy Waterman;Nidhi Aggarwal;Akshta Pai;Wolfgang C. Winkelmayer;Jingbo Niu
  • 通讯作者:
    Jingbo Niu
Increased Pretransplant Inflammatory Biomarkers Predict Death With Function After Kidney Transplantation.
移植前炎症生物标志物增加可预测肾移植后功能死亡。
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Elizabeth C. Lorenz;Byron H Smith;Yun Liang;W. Park;Andrew J. Bentall;A. Dhala;Amy D. Waterman;Cassie C Kennedy;L. Hickson;Andrew D. Rule;Andrea L Cheville;Nathan Lebrasseur;M. Stegall
  • 通讯作者:
    M. Stegall
Primary Care Physicians’ Assessment of the Clinical Utility of A New Prognostic test to Predict the Risk of Kidney Function Decline in Patients with Diabetic Kidney Disease
  • DOI:
    10.1053/j.ajkd.2021.03.003
  • 发表时间:
    2021-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Elizabeth C. Lorenz;John C. Lieske;Barbara M. Seide;Julie B. Olson;Ramila Mehta;Dawn S. Milliner
  • 通讯作者:
    Dawn S. Milliner

Elizabeth C. Lorenz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elizabeth C. Lorenz', 18)}}的其他基金

Improving frailty and long-term outcomes after kidney transplantation
改善肾移植后的虚弱和长期结果
  • 批准号:
    10226292
  • 财政年份:
    2019
  • 资助金额:
    $ 15.88万
  • 项目类别:
Improving frailty and long-term outcomes after kidney transplantation
改善肾移植后的虚弱和长期结果
  • 批准号:
    10662917
  • 财政年份:
    2019
  • 资助金额:
    $ 15.88万
  • 项目类别:
Improving frailty and long-term outcomes after kidney transplantation
改善肾移植后的虚弱和长期结果
  • 批准号:
    10017047
  • 财政年份:
    2019
  • 资助金额:
    $ 15.88万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.88万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了